Femasys Inc. announced that it has appointed Mr. Keith J. Kendall and Mr. Alistair Milnes to its board of directors. Messrs. Kendall and Milnes will be replacing Mr. John Dyett, who currently serves as Co-CEO of Salem Partners, LLC and Salem Partners Wealth Management, LLC and Mr. John Adams, formerly served as CEO and President of Adams Respiratory Therapeutics, who both have served as members of Femasys' board of directors for over eight years.

Mr. Kendall will also replace Mr. Dyett as Audit Committee Chair. Keith J. Kendall serves as Founder and Chief Executive Officer at KSquared Strategic Advisors, a firm that provides strategic, corporate development and capital markets advisory services. Previously, he served as Chief Executive Officer and President of Aquestive Therapeutics, a commercial-stage, biopharmaceutical drug delivery company and prior to that served as their Chief Operating Officer and Chief Financial Officer.

Mr. Kendall has served in various business leadership positions for blue-chip companies such as Hewlett Packard Financial Services, including serving the role of Vice President and Managing Director of the Americas, and held a number of positions with AT&T Capital Corporation, including President of AT&T Credit Corporation and NCR Credit Corporation. Mr. Kendall received his B.S. from St. John's University and an M.B. A from Pace University.

Alistair Milnes serves as Chief Operating Officer at Bicycle Therapeutics, a clinical-stage biopharmaceutical company, and previously served as Vice President, Human Resources and Communications there. Previously, he provided independent human resources consulting services, and also served as a Strategic Advisor at Rio Tinto with a focus on transformation, people and communications, and in roles of increasing responsibility at Gazprom Marketing & Trading Ltd., including serving as Director of Global Human Resources and Communications. Mr. Milnes received his B.A. from Edinburgh Napier University.